新型果糖胺检测在糖尿病患者中的性能及临床意义

Performance and clinical significance of the new fructosamine assay in diabetic patients.

作者信息

Melzi d'Eril G V, Bosoni T, Solerte S B, Fioravanti M, Ferrari E

机构信息

Laboratory of Clinical Chemistry and Neurochemistry, IRCCS Neurological Institute C. Mondino Foundation, University of Pavia, Italy.

出版信息

Wien Klin Wochenschr Suppl. 1990;180:60-3; discussion 78-81.

PMID:2321395

Abstract

The performance of the assay and the clinical usefulness of a new short-term index (Fructosamine Plus: FP) of metabolic control in diabetes was evaluated. The FP concentration was determined with the Hitachi 704, Cobas Mira, and Cobas Fara analyzers. The "within run" and "between run" CVs were less than 2.67% and less than 4.26%, respectively. The reference interval (determined from data on 125 blood donors) was 191 to 288 mumol/l (mean 240 mumol/l). In poorly controlled diabetic patients FP was significantly higher than in the well controlled ones. Moreover FP was significantly correlated with HbA1c and blood glucose levels. Our preliminary data seem to demonstrate that relating FP to total protein does not improve the clinical value of the new index.

摘要

对一种用于评估糖尿病代谢控制的新的短期指标（果糖胺加：FP）的检测性能及其临床实用性进行了评估。使用日立704、Cobas Mira和Cobas Fara分析仪测定FP浓度。批内和批间变异系数分别小于2.67%和小于4.26%。参考区间（根据125名献血者的数据确定）为191至288 μmol/l（平均240 μmol/l）。在血糖控制不佳的糖尿病患者中，FP显著高于血糖控制良好的患者。此外，FP与糖化血红蛋白（HbA1c）和血糖水平显著相关。我们的初步数据似乎表明，将FP与总蛋白相关联并不能提高该新指标的临床价值。